Kofnix SR Tablet (Sustained Release) 50 mg

Kofnix SR Tablet (Sustained Release) 50 mg Uses, Dosage, Side Effects, Food Interaction and all others data.

Kofnix SR Tablet (Sustained Release) 50 mg
Uses
Dosage
Side Effect
Precautions
Interactions
Uses during Pregnancy
Uses during Breastfeeding
Accute Overdose
Food Interaction
Half Life
Volume of Distribution
Clearance
Interaction With other Medicine
Contradiction
Storage

Trade Name	Kofnix SR Tablet (Sustained Release) 50 mg
Generic	Butamirate Citrate
Weight	50 mg
Type	Tablet (Sustained Release)
Therapeutic Class	Cough suppressant
Manufacturer	ACI Limited
Available Country	Bangladesh
Last Updated:	October 19, 2023 at 6:27 am

Uses

Kofnix SR Tablet (Sustained Release) 50 mg is used to relieve dry (non-productive) cough. Dry cough may be caused by a recent viral infection. Kofnix SR Tablet (Sustained Release) 50 mg is also used for pre & post-operative cough sedation in patients who will undergo surgical procedures and bronchoscopy. It can be used in the acute cough of any etiology, whooping cough and cough due to acute lower respiratory tract infections (tracheitis, laryngitis, bronchitis) etc.

Dosage

Kofnix SR Tablet (Sustained Release) 50 mg dosage

Use in adult: Kofnix SR Tablet (Sustained Release) 50 mg 50 mg tablet: 2-3 tablets daily. Kofnix SR Tablet (Sustained Release) 50 mg syrup: 15 ml 4 times daily. Use in children & adolescents:Kofnix SR Tablet (Sustained Release) 50 mg 50 mg tablet: Adolescent over 12 years old: 1-2 tablets daily. Kofnix SR Tablet (Sustained Release) 50 mg syrup: Children (3-6 yrs): 5 ml 3 times daily. Children (6-12 yrs): 10 ml 3 times daily. Adolescent: 15 ml 3 times daily. Kofnix SR Tablet (Sustained Release) 50 mg pediatric drops: Children ( 2 months- 1 yrs): 0.50 ml 4 times daily. Children (1-3 yrs): 0.75 ml 4 times daily.

Side Effects

Tolerance of Kofnix SR Tablet (Sustained Release) 50 mg is good.Adverse reactions such as rash,nausea,diarrhoea and vertigo have been observed in a few rare cases,resolving after dose reduction or treatment withdrawal.

Precaution

Kofnix SR Tablet (Sustained Release) 50 mg suppresses the cough reflex and therefore the concomitant use with expectorants should be avoided, since it may lead to mucus retention in the airways, which increases the risk of bronchospasm and respiratory infections. If the cough persists for more than 7 days (more than 3 days in children younger than12 years of age) doctor must be consulted.

Interaction

Concomitant use with expectorants should be avoided.

Pregnancy & Breastfeeding use

Kofnix SR Tablet (Sustained Release) 50 mg should not be used during the first trimester of pregnancy. During the remainder of pregnancy, it can be used if indicated by a physician but with caution. As a general rule, for safety reasons, in the absence of data on elimination of the active substance in breast milk, the benefits of Kofnix SR Tablet (Sustained Release) 50 mg administration during breast feeding should be carefully weighed against the risks.

Contraindication

Hypersensitivity to the active ingredient.

Acute Overdose

Accidental overdose with Kofnix SR Tablet (Sustained Release) 50 mg can cause the following symptoms: drowsiness, nausea, vomiting, diarrhoea, loss of balance and hypotension. Standard emergency procedures should be followed: activated charcoal, saline laxatives and standard cardio-respiratory resuscitation.